Parkinsonian Syndromes

• CLINICAL_TRIALS trial_result · 2024-10-17
  Clinical Trial Update: Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes [NA]

  Completed clinical trial evaluating 18F-APN-1607 PET imaging to assess tau distribution in tauopathy-related parkinsonism syndromes.

• FDA approval · 2023-09-12
  FDA Approved: IOFLUPANE I 123 — Supplemental Application (Curium US LLC)

  FDA approved a supplemental application for IOFLUPANE I-123 (DaTSCAN) from Curium US LLC.

• FDA approval · 2022-11-01
  FDA Approved: DATSCAN — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)

  FDA approved a supplemental application for DATSCAN (ioflupane I-123) by Medi-Physics Inc. dba GE Healthcare.

• FDA approval · 2022-03-30
  FDA Approved: IOFLUPANE I 123 — Original Application (Curium US LLC)

  The FDA approved IOFLUPANE I-123 (IOFLUPANE I-123) from Curium US LLC in an Original Application as a dopamine transporter imaging agent for…

• FDA approval · 2011-01-14
  FDA Approved: DATSCAN — Original Application (Medi-Physics Inc. dba GE Healthcare.)

  FDA approved the original application for DATSCAN (ioflupane I-123), a radiopharmaceutical for brain imaging to aid in differentiating Parki…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2010-02-03
  Clinical Trial Update: Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor [Phase 3]

  Two Phase 3 studies are evaluating ALTROPANE for SPECT imaging of upper-extremity tremor in Parkinsonian syndromes; the current status of th…